Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A | P11388 | 1/20 | 0.44 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.40 |
| ▸ | CCKBR | P32239 | 1/20 | 0.37 |
| ▸ | PLA2G10 | O15496 | 3/20 | 0.36 |
| ▸ | PLA2G2A | P14555 | 3/20 | 0.36 |
| ▸ | PLA2G5 | P39877 | 3/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
| ▸ | BCR | P11274 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | GALR2 | O43603 | 1/20 | 0.36 |
| ▸ | GALR1 | P47211 | 1/20 | 0.36 |
| ▸ | ALPL | P05186 | 1/20 | 0.35 |
| ▸ | ALPI | P09923 | 1/20 | 0.35 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2956411 | 0.89 | TOP2A (0.42) | TOP2ACHRNA7CCKBRPPARG | |
| SCHEMBL2960203 | 0.86 | MAPT (0.45) | PLA2G10 | |
| SCHEMBL2958575 | 0.84 | CDK4 (0.38) | PDE4B | |
| SCHEMBL2951770 | 0.84 | C1R (0.37) | EPHX2 | |
| SCHEMBL2960252 | 0.84 | UBE2M (0.36) | PDE4B | |
| SCHEMBL2956783 | 0.83 | PDE4B (0.42) | TOP2APDE4B | |
| SCHEMBL2952784 | 0.83 | NPC1 (0.41) | CHRNA7PDE4B | |
| SCHEMBL2955616 | 0.83 | TDO2 (0.41) | — | |
| SCHEMBL2956387 | 0.83 | MAPT (0.43) | CHRNA7PPARG | |
| SCHEMBL2960395 | 0.83 | TOP2A (0.41) | TOP2ACCKBREPHX2GALR2GALR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7423047-B2 | Arylamine substituted bicyclic heteroaromatic compounds as p38 kinase inhibitors | CELLTECH R&D LIMITED (GB) | 2008-09-09 | — | — | US | claimed |
| US-20060004025-A1 | Arylamine substututed bicyclic heteroaromatic compounds as p38 kinase inhibitors | UCB PHARMA S.A. (BE) | 2006-01-05 | — | — | US | claimed |
| US-7763729-B2 | Bicyclic heteroaromatic derivatives | UCB PHARMA S.A. (BE) | 2010-07-27 | — | — | US | disclosed |
| US-20090042877-A1 | Bicyclic Heteroaromatic Derivatives | CELLTECH R&D LIMITED (GB) | 2009-02-12 | — | — | US | disclosed |
| US-7423047-B2 | Arylamine substituted bicyclic heteroaromatic compounds as p38 kinase inhibitors | CELLTECH R&D LIMITED (GB) | 2008-09-09 | — | — | US | disclosed |
| US-20060004025-A1 | Arylamine substututed bicyclic heteroaromatic compounds as p38 kinase inhibitors | UCB PHARMA S.A. (BE) | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004025-A1 | Arylamine substututed bicyclic heteroaromatic compounds as p38 kinase inhibitors | MAPK1, CNKSR1, ALK | TOP2A 3464/4885CHRNA7 1817/4885CCKBR 1246/4885 |
| US-20090042877-A1 | Bicyclic Heteroaromatic Derivatives | MAPK1, CNKSR1, CBR1 | TOP2A 3000/4885CHRNA7 2079/4885CCKBR 1083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.